Table 1.
Patients characteristics
| Characteristics | Patients (%) |
RRM1 mean |
ERCC1 mean |
BRCA1 mean |
|---|---|---|---|---|
| All patients | ||||
| (median age 54 y, range 35–78) | 55(100%) | 1,237.00 | 229.6 | 794.1 |
| Stage at diagnosis | ||||
| Localized | 47 (85.5%) | 1.271.7 | 235.8 | 849.9 |
| Advanced | 8 (14.5%) | 1,126.10 | 198.2 | 560.1 |
| Histotype | ||||
| Ductal carcinoma | 43 (78%) | 1,294.50 | 227.2 | 833 |
| Other | 12 (22%) | 1,079.20 | 251.1 | 697 |
| Grading | ||||
| 1 | 3 (5.5%) | 1,182.80 | 179.3 | 644.9 |
| 2 | 15 (27%) | 1,252.10 | 235.7 | 808.1 |
| 3 | 25 (45.5%) | 1,265.10 | 228.2 | 806.3 |
| Not available | 12 (22%) | 1,173.70 | 233 | 777.6 |
| Hormone receptor | ||||
| ER and/or PgR positive | 40 (73%) | 1,236.90 | 227.5 | 818.1 |
| ER and PgR negative | 13 (23.5%) | 1,355.40 | 251.8 | 816.7 |
| Not available | 2 (3.5%) | 468.3 | 126.9 | 167.9 |
| HER2 status | ||||
| HER2 positive | 6 (11%) | 1,248.60 | 208.1 | 975.7 |
| HER2 negative | 47 (85.5%) | 1,236.20 | 232.9 | 784.2 |
| Not available | 2 (3.5%) | 1,220.60 | 216.2 | 482.1 |
| Prior anthracyclines* | 55 (100%) | 1,237.00 | 229.6 | 794.1 |
| Prior taxanes* | 9 (16.5%) | 928.5 | 219.5 | 542.5 |
| Visceral disease | ||||
| Yes | 43 (78%) | 1,172.80 | 230.4 | 765.7 |
| No | 12 (22%) | 1,466.80 | 226.9 | 895.9 |
| Prior chemotherapies for MBC | ||||
| 0 | 22 (40%) | 1,395.00 | 243.3 | 873.8 |
| 1 | 33 (60%) | 1,188.80 | 226 | 830.8 |
| Type of gemcitabine-based chemotherapy | ||||
| Gemcitabine plus a taxane† | 46 (83.5%) | 1,297.30 | 231.6 | 843.3 |
| Gemcitabine plus PLD § | 9 (16.5%) | 928.5 | 219.5 | 542.5 |
MBC, metastatic breast cancer; PLD, pegylated liposomal doxorubicin
*
Either in the adjuvant or metastatic setting
†
Gemcitabine 1250 mg/m2 dd 1,8 – paclitaxel 175 mg/m2 d 1 q 21 (35 patients, 63.5%); gemcitabine 1000 mg/m2 dd 1,8 – docetaxel 80 mg/m2 d 8 q 21 (11 patients, 20%)
§
Gemcitabine 800 mg/m2 dd 1,8 – pegylated liposomal doxorubicin 25 mg/m2 d 8 q 21